Carol Burt has served as a ResMed director since November 2013 and is chair of the audit and compliance oversight committees. She is also a member of the nominating and governance committee.

Ms. Burt, principal of Burt-Hilliard Investments is a private investor with more than 35 years experience in corporate governance, operations, strategy, finance, mergers and acquisition and investment banking. Since 2013, Ms. Burt has served as a senior advisor and a member of the operating council of Consonance Capital Partners, a New York-based private equity firm focused on investments in the healthcare industry. Ms. Burt serves on the boards of IQVIA Holdings Inc. (NYSE: IQV), where she is a member of the audit committee and chair of the leadership development and compensation committee; and two private companies, Global Medical Response and WellDyne.

Prior to their sale, Ms. Burt served on the public boards of Envision Healthcare, Transitional Hospitals, Vanguard Health Systems, WellCare Health Plans, and private-equity-backed KEPRO.

Ms. Burt was formerly senior vice president corporate finance and development of WellPoint, Inc. (now Anthem, Inc.) where she was part of the executive team that built WellPoint from a single state health plan to one of the leading health benefits companies in the US. Ms. Burt was responsible for, among other things, corporate strategic planning and execution, mergers and acquisitions, strategic and venture investments, financial reporting, budgeting and forecasting, treasury, business information systems and real estate management. In addition, WellPoint’s financial services and international insurance business units reported to her.

Before WellPoint, Ms. Burt was senior vice president and treasurer of American Medical Response. Previously, she spent 16 years at Chase Securities, Inc., now JP Morgan Chase & Co (NYSE: JPM), most recently as founder, managing director and head of the Health Care Banking Group.

Ms. Burt is a member of Women Corporate Directors and the International Women’s Forum. Her philanthropic activities focus on mentoring women for leadership positions and environmental causes.

Ms. Burt graduated magna cum laude from the University of Houston, earning a Bachelor of Business Administration.

Ms. Burt’s executive management and board experience in the health insurance, healthcare services, medical technology and financial services industries led the board to the conclusion that she should serve as a director.

Karen Drexler has served as a ResMed director since November 2017, and is a member of the compensation and nominating and governance committees.

Ms. Drexler is a serial entrepreneur with expertise in the fields of digital health, medical devices, and diagnostics. Currently, she serves on the boards of Outset Medical (NASDAQ: OM), a medtech company innovating dialysis treatment; Tivic Health (NASDAQ: TIVC), a bioelectric medicine company focused on relief of congestion and sinus pain; VIDA Diagnostics, the leading company in Al-powered lung intelligence solutions; EBR Systems, Inc. (ASX: EBR), maker of a wireless cardiac pacing system for people with heart failure; and Huma.ai, a company using natural language queries to extract unique insights from complex medical data.

From 2016 to 2020, Ms. Drexler was the CEO and a board member of Sandstone Diagnostics, Inc., a private company developing instruments and consumables for point-of-care medical testing. From 2011 to 2017, she served as board chair of Hygieia, Inc., a digital insulin therapy company, and remains involved as an advisor to the CEO. She also acts as a senior strategic advisor for several other early-stage companies, and spent 11 years on the board of the Keller Center for Innovation in Engineering Education at Princeton University.

Ms. Drexler is an active mentor and advisor with Astia, a global nonprofit that supports high-potential female founders. She is a founding member of Astia Angels, a network of individual investors who fund such founders, and a lead mentor with StartX, the Stanford University incubator. She is also on the Life Science and Women’s Health Councils for Springboard, an accelerator for women-led technology-oriented companies. Through her work with Astia, Springboard, and StartX, she interacts with many promising young medtech companies.

Ms. Drexler was founder, president, and CEO of Amira Medical Inc., a private company focused on minimally invasive glucose monitoring technology, from 1996 until it was sold to Roche Holding AG in 2001. Before Amira Medical, she held management roles at LifeScan and played a key role in its sale to Johnson & Johnson (NYSE: JNJ).

Ms. Drexler graduated magna cum laude with a B.S.E. in chemical engineering from Princeton University, and earned an M.B.A. with honors from the Stanford University Graduate School of Business.

Michael “Mick” Farrell was appointed ResMed’s CEO and has served as a director since March 2013. In January 2023, he was appointed chair of our board of directors. Mick joined the company in 2000, serving as president of the Americas region from 2011 to 2013, senior vice president of the global sleep apnea business unit from 2007 to 2011, and various senior roles in marketing and business development.

Before joining ResMed, Mick worked in management consulting, biotechnology, chemicals and metals manufacturing at companies including Arthur D. Little, Sanofi Genzyme, Dow Chemical, and BHP.

Mick serves on the board of directors of the Advanced Medical Technology Association (AdvaMed) and Zimmer Biomet (NYSE: ZBH), a global provider of implantable musculoskeletal medical devices. He is a member of two committees at Zimmer Biomet: the compensation and management development committee, as well as the quality, regulatory, and technology committee, of which he is chair. Mick also volunteers as a trustee for non-profit organizations: UC San Diego Foundation, Rady Children’s Hospital, and Father Joe’s Villages’ project for the homeless in San Diego, California.

Mick holds a Bachelor of Engineering with first-class honors from the University of New South Wales, a Master of Science in chemical engineering from the Massachusetts Institute of Technology (MIT), and a Master of Business Administration from the MIT Sloan School of Management.

John Hernandez has served as a ResMed director since November 2021, and is a member of the compliance oversight committee.

Dr. Hernandez is head of clinical research, health economics, and outcomes research at Google (NASDAQ: GOOGL). He joined Alphabet in 2016 where he has built and led teams at Verily and Google leveraging artificial intelligence to assist in promoting healthy lifestyles, diagnosing cancer, preventing blindness, and more. He serves on the board of directors of Carmat, SA (ALCAR.PA), a publicly traded French artificial heart company, where he is a member of the audit and R&D committees.

Dr. Hernandez is a medical device and digital health executive with over 30 years of experience in clinical research, health economics, market access, and global commercial strategy. Prior to joining Alphabet, he was vice president of global health economics and outcomes research at Abbott Laboratories (NYSE: ABT), and vice president of health economics and clinical research at Boston Scientific Corporation (NYSE: BSX). He has also been an adjunct faculty member at Stanford University and served in health services research, strategy consulting, and health policy roles at the RAND Corporation, Quintiles, PwC, and the American Society of Internal Medicine (now ACP). 

Dr. Hernandez is widely published in scientific journals and is a frequent healthcare lecturer. He holds a PhD and Masters in Health Policy from the RAND Graduate School in Santa Monica, Calif., and a bachelor’s in political science from the University of North Carolina at Chapel Hill.

Desney Tan has served as a ResMed director since November 2021, and is a member of the compensation committee.

Dr. Desney Tan is vice president and managing director for Health and Life Science R&D at Microsoft (NASDAQ: MSFT), where he’s worked in various leading research roles since 2004. He is also an affiliate professor of computer science and engineering at the University of Washington Seattle since 2007, where he cofounded the National Science Foundation Center for Sensorimotor Neural Engineering and chaired its industry advisory board. 

Dr. Tan is a seasoned executive who has built and run multidisciplinary global innovation teams – leveraging expertise in hardware and devices, software development, applied machine learning and artificial intelligence, human-computer interaction, and applied science to make impact in areas such as autonomous navigation, entertainment and consumer products, as well as health and life sciences.

Dr. Tan is the named inventor on more than 100 granted patents, and author of numerous academic publications on topics relevant to ResMed’s long-term strategy such as artificial intelligence, machine learning, and human-computer interaction. He serves on the board of two private companies: 1910 Genetics, a biotechnology company integrating artificial intelligence, computation, and biological automation to improve drug development; and Artificial, a lab automation company focused on accelerating the pace of life science discoveries. He also serves on the Washington Research Foundation’s board of directors; as senior advisor and chief technologist to IntuitiveX, a medical device and life sciences innovation partner and catalyst; and as advisor to Proprio, which is developing an advanced surgical navigation platform. He achieved the rank of Lieutenant in the Singapore Armed Forces over two-and-a-half years of active duty service, and still serves in its reserves

Dr. Tan has a Ph.D. in computer science from Carnegie Mellon University, and a Bachelor of Science in computer engineering from the University of Notre Dame.